Share on StockTwits

Cara Therapeutics (NASDAQ:CARA) released its earnings data on Thursday. The company reported ($0.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.27) by $0.11, Stock Ratings Network.com reports. The company had revenue of $0.96 million for the quarter, compared to the consensus estimate of $0.08 million. Cara Therapeutics’s revenue was down 90.4% compared to the same quarter last year.

On a related note, analysts at Canaccord Genuity raised their price target on shares of Cara Therapeutics from $25.00 to $29.00 in a research note on Thursday, May 15th. Four analysts have rated the stock with a buy rating, Cara Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $25.00.

Cara Therapeutics (NASDAQ:CARA) traded down 6.49% during mid-day trading on Thursday, hitting $10.80. 71,590 shares of the company’s stock traded hands. Cara Therapeutics has a one year low of $10.40 and a one year high of $23.25. The stock’s 50-day moving average is $14.22 and its 200-day moving average is $15.13. The company’s market cap is $244.1 million.

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.